COMP <GO>
RXST vs UNH // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
RxSight Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: RXST 0
— UNH 11
■ METRIC PARITY
LAST: $5.05 (+3.06%) • MKT CAP: $210.0M
options-implied-move
—
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
options-implied-move
6.74%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXST VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXST | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 76.60% | 88.57% | -11.97 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.90% | 11.47% | -26.37 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.21% | 6.48% | -15.69 | UNH | /fcf-yield <GO> |
| Operating Margin | -35.80% | 4.82% | -40.62 | UNH | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 3.14% | -3.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -3.90% | 6.46% | -10.36 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.45 | 3.12 | -1.67 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 7/9 | -5.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 59.2 | -6.90 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $210.0M | $368.83B | -$368.62B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXST REV | UNH REV | RXST GROSS % | UNH GROSS % | RXST FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $134.5M | $447.57B | 76.6% | 88.7% | -$19.3M | $16.07B |
| FY 2024 | $139.9M | $400.28B | 70.7% | 88.3% | -$22.4M | $20.70B |
| FY 2023 | $89.1M | $371.62B | — | 89.6% | -$41.6M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXST // BETA —
UNH // BETA 0.33